Sleep deprivation reduces the lymphocyte count in a non-obese mouse model of type 1 diabetes mellitus

被引:5
|
作者
Ruiz, F. S. [1 ]
Andersen, M. L. [1 ]
Zager, A. [1 ]
Martins, R. C. S. [1 ]
Tufik, S. [1 ]
机构
[1] Univ Fed Sao Paulo, Dept Psicobiol, Escola Paulista Med, BR-04024002 Sao Paulo, SP, Brazil
关键词
sleep deprivation; stress; lymphopenia; diabetes; non-obese diabetic mouse; Swiss mice;
D O I
10.1590/S0100-879X2006005000086
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The objective of the present study was to determine whether sleep deprivation ( SD) would promote changes in lymphocyte numbers in a type 1 diabetes model (non-obese diabetic, NOD, mouse strain) and to determine whether SD would affect female and male NOD compared to Swiss mice. The number of lymphocytes in peripheral blood after 24 and 96 h of SD ( by multiple platform method) or equivalent period of time in home-cage controls was examined prior to the onset of diabetes. SD for 96 h significantly reduced lymphocytes in male Swiss mice compared to control (8.6 +/- 2.1 vs 4.1 +/- 0.7 10(3)/mu L; P < 0.02). In male NOD animals, 24- and 96-h SD caused a significant decrease of lymphocytes compared to control ( 4.4 +/- 0.3 vs 1.6 +/- 0.5; P < 0.001 and 4.4 +/- 0.3 vs 0.9 +/- 0.1 10(3)/mu L; P < 0.00001, respectively). Both 24- and 96- h SD induced a reduction in the number of lymphocytes in female Swiss ( 7.5 +/- 0.5 vs 4.5 +/- 0.5, 4.4 +/- 0.6 +/- 103/ L; P < 0.001, respectively) and NOD mice (4 +/- 0.6 vs 1.8 +/- 0.2, 1.2 +/- 0.4 10(3)/ L; P < 0.01, respectively) compared to the respective controls. Loss of sleep induced lymphopenia in peripheral blood in both genders and strains used. Since many cases of autoimmunity present reduced numbers of lymphocytes and, in this study, it was more evident in the NOD strain, our results suggest that SD should be considered a risk factor in the onset of autoimmune disorders.
引用
收藏
页码:633 / 637
页数:5
相关论文
共 50 条
  • [31] The Pathophysiology of Type 2 Diabetes Mellitus in Non-obese Individuals: An Overview of the Current Understanding
    Olaogun, Idowu
    Farag, Mina
    Hamid, Pousettef
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (04)
  • [32] DIETARY PREVENTION OF DIABETES IN THE NON-OBESE DIABETIC MOUSE
    ELLIOTT, RB
    REDDY, SN
    BIBBY, NJ
    KIDA, K
    DIABETOLOGIA, 1988, 31 (01) : 62 - 64
  • [33] The non-obese diabetic mouse sequence, annotation and variation resource: an aid for investigating type 1 diabetes
    Steward, Charles A.
    Gonzalez, Jose M.
    Trevanion, Steve
    Sheppard, Dan
    Kerry, Giselle
    Gilbert, James G. R.
    Wicker, Linda S.
    Rogers, Jane
    Harrow, Jennifer L.
    DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION, 2013,
  • [34] Carbamazepine protects pancreatic beta cells and reduces type 1 diabetes incidence in non-obese diabetic mice
    Lee, J. T. C.
    Shanina, I.
    Horwitz, M. S.
    Johnson, J. D.
    DIABETOLOGIA, 2016, 59 : S215 - S215
  • [35] Progressive myelopathy associated with spinal epidural lipomatosis in three non-obese patients with type 1 diabetes mellitus
    Lotan, Itay
    Charlson, Robert W.
    Fatterpekar, Girish M.
    Shapiro, Maksim
    Smith, Michael L.
    William, Christopher
    Kister, Ilya
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 411
  • [36] Non-Obese MKR Mouse Model of Type 2 Diabetes Reveals Skeletal Alterations in Mineralization and Material Properties
    Tice, Matthew J. L.
    Bailey, Stacyann
    Sroga, Grazyna E.
    Gallagher, Emily J.
    Vashishth, Deepak
    JBMR PLUS, 2022, 6 (02)
  • [37] The Difference Levels of Hepcidin and Interleukin-6 between Obese and Non-Obese Type 2 Diabetes Mellitus
    Maherdika, Mabruratussania
    Samsuria, Indranila Kustarini
    Hendrianingtyas, Meita
    Widyastiti, Nyoman Suci
    Rahayu, Muji
    INDONESIAN BIOMEDICAL JOURNAL, 2022, 14 (01): : 98 - 103
  • [38] Alterations in Choline Metabolism in Non-Obese Individuals with Insulin Resistance and Type 2 Diabetes Mellitus
    Al-Sulaiti, Haya
    Anwardeen, Najeha
    Bashraheel, Sara S.
    Naja, Khaled
    Elrayess, Mohamed A.
    METABOLITES, 2024, 14 (08)
  • [39] Cholesterol metabolism in obese and non-obese subjects with type 2 diabetes
    Simonen, PP
    Gylling, HK
    Miettinen, TA
    CIRCULATION, 2000, 102 (18) : 283 - 283
  • [40] Rosiglitazone is effective in obese and non-obese patients with Type 2 diabetes
    Deacon, L
    Donnelly, S
    Stewart, M
    Hand, L
    DIABETES, 2001, 50 : A433 - A433